• Furthermore we argued that an inability

  2022-03-11

  

  Furthermore, we argued that an inability to encode or monitor the temporal sequence of events or episodes in order to discriminate between other similar or related events (encoding what-happened-when) could result in an increased susceptibility to proactive interference and, thus, in principle expla

• If some of the experimentally determined tRNAGlu identity el

  2022-03-11

  

  If some of the experimentally determined tRNAGlu identity elements are unique to E. coli, then there also must be some unique phylum-specific residues in the corresponding GluRS (E. coli in particular, and proteobacteria in general) as well. In this paper we focus on identifying such residues in E.

• Herein in consider of the high similarity

  2022-03-10

  

  Herein, in consider of the high similarity between GR HBP site and AR HBP site, we applied rational drug design strategy to develop AR/GR antagonists based on the chemical structures of antiandrogens and crystal structure of GR. The following bioassay identified Z19 as a dual AR/GR antagonist. Z19 i

• At the end of experiments rats

  2022-03-10

  

  At the end of experiments rats were injected high dose of sodium pentobarbital (90mg/kg) and the rat’s head was cut and frozen in −20°C for 20min with the injecting tube in situ before section. The location of the tip of the injecting tube was verified and all the tips of the injecting tube were in

• Drosophila is a well established model to investigate

  2022-03-10

  

  Drosophila is a well-established model to investigate the molecular and cellular defects underlying human neurodevelopmental disorders (Oortveld et al., 2013, van der Voet et al., 2014). Here, we establish Drosophila as a model for understanding the mechanisms linking mutations in KDM5 family protei

• With LML methyl oxo dihydropyridazin yl piperidin yl cyclobu

  2022-03-10

  

  With LML-134 (1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-cyclobutylpiperazine-1-carboxylate) containing drug-likeness properties (MW 375.47, five HBA, and MLogP 1.88), Novartis presents an additional drug-candidate to treat excessive sleepiness. A phase I clinical study was perform

• Of the many thousands of mutations analyzed in tracheal

  2022-03-10

  

  Of the many thousands of mutations analyzed in tracheal terminal cells, less than a handful affect tube morphology specifically in the transition zone (Baer et al., 2007, Beitel and Krasnow, 2000, Förster et al., 2010, Ghabrial et al., 2011, Myat et al., 2005, Ruiz et al., 2012, Samakovlis et al., 1

• Recently it has been found

  2022-03-10

  

  Recently, it has been found that treatment of human phagocytic Bay 11-7085 or microvascular endothelial cells with NO donors inhibited the O2− generating capacity of NADPH oxidase [[8], [9], [10], [11]], which may involve down-regulation or S‑nitrosylation of the p47phox subunit (a cytosolic subuni

• br Conclusion Infections caused by the P aeruginosa could no

  2022-03-10

  

  Conclusion Infections caused by the P. aeruginosa could not be cured by current antibiotics, making multiple drug resistance of P. aeruginosa an increasing threat for human lives. Looking for a new therapeutic mechanism for infections caused by the P. aeruginosa has become a central issue. There

• br Conclusion The development discovery of compounds targeti

  2022-03-10

  

  Conclusion The development/discovery of compounds targeting small GTPases is challenging [43,44]. Our data point to RBC8 being efficient and potent as a Ral inhibitor in human and mouse platelets, but that it exhibits some activity beyond just Rals, particularly in mouse platelets. It is however

• Cdc is also linked to the adherens junction

  2022-03-10

  

  Cdc42 is also linked to the adherens junction via IQGAP1, however, it appears to have an opposite effect on junctional stability. When Cdc42 is inactive, IQGAP1 binds to β-catenin, displacing α-catenin, resulting in the loss of α-catenin-linked AICAR filaments from the adherens junction and reduced

• Pharmacologic approaches of inhibiting GSNOR activity have

  2022-03-10

  

  Pharmacologic approaches of inhibiting GSNOR activity have reached the point of clinical development with the recent announcement of the first cystic fibrosis patients treated with the first-in-class GSNOR inhibitor, N6022 (N30 Pharmaceuticals). Clinical development is ongoing for other indications

• We recently reported that the human derived

  2022-03-09

  

  We recently reported that the human-derived PancCa cell line PANC-1 and the human-derived hepatocellular HepG2 cell line express GPR55 mRNA and protein [21]. In PANC-1 and HepG2 cells, knockdown of GPR55 with specific siRNAs abrogates cellular uptake of Tocrifluor 1117, a selective GPR55 ligand [21]

• The pharmacokinetics of was obtained

  2022-03-09

  

  The pharmacokinetics of was obtained in mouse, rat and dog to determine if it had a suitable profile to investigate the effects of the GPR120 mechanism (). had an adequate half-life, low clearance in all 3 species, and high blood levels and bioavailability. The low volume of distribution (V) indi

• br Introduction High dose niacin or nicotinic acid has been

  2022-03-09

  

  Introduction High dose niacin, or nicotinic acid, has been used as an athero-protective drug for more than 50 years (Carlson, 2005, Offermanns, 2006). When taken in pharmacological doses (>1g/day), the nicotinic Caspase-2 Colorimetric Assay Kit form of niacin modulates plasma lipid profiles inc

15846 records 463/1057 page Previous Next First page 上5页 461462463464465 下5页 Last page